Evidence map›Paper›PMID 39740812›Full record

ArticleAnticancer research2025

How to Predict Recurrence After Resection of Hepatocellular Carcinoma.

Natalie Petruch, Louisa Bolm, Martina Nebbia, Shahrzad Arya, Marco Ventin, Motaz Qadan, Nahel Elias, Jannis Duhn, Dirk Rades, Leigh A Dageforde and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Anticancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Log-transformed α-Fetoprotein andIn vivo (Athens, Greece)
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Natalie Petruch *Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, U.S.A.
Louisa Bolm *Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, U.S.A.
Martina NebbiaDepartment of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, U.S.A.
Shahrzad AryaDepartment of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, U.S.A.
Marco VentinDepartment of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, U.S.A.
Motaz QadanDepartment of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, U.S.A.
Nahel EliasDepartment of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, U.S.A.
Jannis DuhnDepartment of Surgery, University Medical Center Schleswig-Holstein, Lübeck, Germany.
Dirk RadesDepartment of Radiation Oncology, University of Lübeck, Lübeck, Germany.
Leigh A DagefordeDepartment of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, U.S.A.
Kenneth T TanabeDepartment of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, U.S.A.
Joseph FransesDepartment of Medical Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, U.S.A.
Vikram DeshpandeDepartment of Pathology, Beth Israel Medical Center, New York, NY, U.S.A.
Ulrich F WellnerDepartment of Surgery, University Medical Center Schleswig-Holstein, Lübeck, Germany.
Tobias KeckDepartment of Surgery, University Medical Center Schleswig-Holstein, Lübeck, Germany.
Onofrio CatalanoDepartment of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, U.S.A.
Cristina R FerroneDepartment of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, U.S.A.; Cristina.Ferrone@cshs.org.

Funding

Development and Testing of an Integrated Care Coordination Intervention for Alcohol Use Disorder Recovery after Liver TransplantationK23AA031068 · NIAAA · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Leigh Anne Dageforde · 2023 to 2026
$749k
NIAAA NIH HHS K23 AA031068
6 · The paper itself

Abstract

BACKGROUND/

aimPredictors of recurrence following resection of hepatocellular carcinoma (HCC) are not fully established. This study investigated potential risk factors and prognostic scores for this situation. PATIENTS AND

methodsIn 297 patients undergoing resection of HCC between 2000 and 2021, risk scores and potential additional risk factors for intrahepatic and extrahepatic recurrence were assessed.

resultsMedian overall survival was 48.4 months, median time to recurrence 25.1 months. The Alpha-Fetoprotein (AFP)-score differentiated between low and high-risk groups (21.8 vs. 8.3 months, p=0.001), as did the Risk Estimation of Tumor Recurrence After Transplant (RETREAT)-score (16 vs. 9 months, p=0.004) and the Clinical Risk Score (CRS) (14.9 vs. 3.9 months, p=0.002). Advanced T-stage, multiple lesions, and vessel infiltration were significantly associated with any type of recurrence, advanced T-stage, and multiple lesions with intrahepatic recurrence.

conclusionPredictors of recurrence following resection of HCC were identified. Prognostic scores traditionally used for patients receiving liver transplantation (AFP-score, RETREAT-score, CRS) were predictive also of recurrence after resection of HCC.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsNeoplasm Recurrence, LocalAdultAgedAged, 80 and overalpha-FetoproteinsFemaleHepatectomyHumansLiver TransplantationMaleMiddle AgedNeoplasm StagingPrognosisRisk Factorsalpha-FetoproteinsHepatocellular carcinomaprognostic scorerecurrencesurgcal resection

Identifiers

PMID39740812
PMCPMC13250944

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.